TABLE OF CONTENTS
1 INTRODUCTION 117
1.1 OBJECTIVES OF THE STUDY 117
1.2 MARKET DEFINITION 117
1.3 OVERVIEW OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET 117
1.4 CURRENCY AND PRICING 119
1.5 LIMITATIONS 119
1.6 MARKETS COVERED 119
2 MARKET SEGMENTATION 127
2.1 MARKETS COVERED 127
2.2 GEOGRAPHICAL SCOPE 128
2.3 YEARS CONSIDERED FOR THE STUDY 129
2.4 DBMR TRIPOD DATA VALIDATION MODEL 130
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 133
2.6 MULTIVARIATE MODELLING 134
2.7 MARKET APPLICATION COVERAGE GRID 135
2.8 INSTRUMENT BASED LIFELINE CURVE 136
2.9 DBMR MARKET POSITION GRID 137
2.10 VENDOR SHARE ANALYSIS 139
2.11 SECONDARY SOURCES 140
2.12 ASSUMPTIONS 140
3 EXECUTIVE SUMMARY 141
4 PREMIUM INSIGHTS 144
4.1 PESTEL ANALYSIS 145
4.2 PORTERS FIVE FORCES 146
4.3 PATENT ANALYSIS OF NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET 147
4.4 REIMBURSEMENT SCENARIO 148
4.5 INDUSTRY INSIGHTS: 149
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 149
4.7 PRICING STRATEGIES 149
4.8 CONCLUSION 150
4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 151
4.10 COST OF UTERINE CANCER PROCEDURE 153
5 REGULATORY FRAMEWORK 154
6 MARKET OVERVIEW 156
6.1 DRIVERS 158
6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 158
6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 158
6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 159
6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 159
6.2 RESTRAINTS 160
6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 160
6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 160
6.3 OPPORTUNITIES 161
6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 161
6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 161
6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 162
6.4 CHALLENGES 162
6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 162
6.4.2 HIGH COST OF IMAGING SYSTEMS 163
7 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 164
7.1 OVERVIEW 165
7.2 INSTRUMENT-BASED 168
7.2.1 ULTRASOUND SCANNING 169
7.2.1.1 SYSTEMS 169
7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 170
7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 170
7.2.1.4 ACCESSORIES 170
7.2.2 IMAGING DEVICES 170
7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 171
7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 171
7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 171
7.2.2.4 OTHERS 171
7.2.3 TESTS 172
7.2.3.1 BLOOD TESTS 172
7.2.3.1.1 COMPLETE BLOOD COUNT 172
7.2.3.1.2 CA125 MARKER BLOOD TEST 172
7.2.3.2 URINE TESTS 173
7.2.3.3 OTHER TESTS 173
7.2.4 OTHERS 173
7.3 PROCEDURE BASED 173
7.3.1 ENDOMETRIAL BIOPSY 174
7.3.2 HYSTEROSCOPY 174
7.3.3 DILATION & CURETTAGE 174
7.3.4 CYSTOSCOPY 174
7.3.5 PROCTOSCOPY 175
7.3.6 OTHERS 175
8 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 176
8.1 OVERVIEW 177
8.2 ENDOMETRIAL CANCER 180
8.2.1 SEROUS ADENOCARCINOMA 181
8.2.1.1 INSTRUMENT-BASED 181
8.2.1.1.1 ULTRASOUND SCANNING 182
8.2.1.1.2 IMAGING DEVICES 182
8.2.1.1.3 TESTS 182
8.2.1.1.4 OTHERS 182
8.2.1.2 PROCEDURE-BASED 183
8.2.1.2.1 ENDOMETRIAL BIOPSY 183
8.2.1.2.2 HYSTEROSCOPY 183
8.2.1.2.3 DILATION & CURETTAGE 183
8.2.1.2.4 CYSTOSCOPY 183
8.2.1.2.5 PROCTOSCOPY 183
8.2.1.2.6 OTHERS 184
8.2.2 ADENOSQUAMOUS CARCINOMA 184
8.2.2.1 INSTRUMENT-BASED 184
8.2.2.1.1 ULTRASOUND SCANNING 184
8.2.2.1.2 IMAGING DEVICES 185
8.2.2.1.3 TESTS 185
8.2.2.1.4 OTHERS 185
8.2.2.2 PROCEDURE-BASED 185
8.2.2.2.1 ENDOMETRIAL BIOPSY 185
8.2.2.2.2 HYSTEROSCOPY 185
8.2.2.2.3 DILATION & CURETTAGE 186
8.2.2.2.4 CYSTOSCOPY 186
8.2.2.2.5 PROCTOSCOPY 186
8.2.2.2.6 OTHERS 186
8.2.3 UTERINE CARCINOSARCOMA 186
8.2.3.1 INSTRUMENT-BASED 186
8.2.3.1.1 ULTRASOUND SCANNING 187
8.2.3.1.2 IMAGING DEVICES 187
8.2.3.1.3 TESTS 187
8.2.3.1.4 OTHERS 187
8.2.3.2 PROCEDURE-BASED 188
8.2.3.2.1 ENDOMETRIAL BIOPSY 188
8.2.3.2.2 HYSTEROSCOPY 188
8.2.3.2.3 DILATION & CURETTAGE 188
8.2.3.2.4 CYSTOSCOPY 188
8.2.3.2.5 PROCTOSCOPY 188
8.2.3.2.6 OTHERS 189
8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 189
8.2.4.1 INSTRUMENT-BASED 189
8.2.4.1.1 ULTRASOUND SCANNING 189
8.2.4.1.2 IMAGING DEVICES 190
8.2.4.1.3 TESTS 190
8.2.4.1.4 OTHERS 190
8.2.4.2 PROCEDURE-BASED 190
8.2.4.2.1 ENDOMETRIAL BIOPSY 190
8.2.4.2.2 HYSTEROSCOPY 190
8.2.4.2.3 DILATION & CURETTAGE 191
8.2.4.2.4 CYSTOSCOPY 191
8.2.4.2.5 PROCTOSCOPY 191
8.2.4.2.6 OTHERS 191
8.3 UTERINE SARCOMA 191
8.3.1 LEIOMYOSARCOMA 192
8.3.1.1 INSTRUMENT-BASED 192
8.3.1.1.1 ULTRASOUND SCANNING 193
8.3.1.1.2 IMAGING DEVICES 193
8.3.1.1.3 TESTS 193
8.3.1.1.4 OTHERS 193
8.3.1.2 PROCEDURE-BASED 194
8.3.1.2.1 ENDOMETRIAL BIOPSY 194
8.3.1.2.2 HYSTEROSCOPY 194
8.3.1.2.3 DILATION & CURETTAGE 194
8.3.1.2.4 CYSTOSCOPY 194
8.3.1.2.5 PROCTOSCOPY 194
8.3.1.2.6 OTHERS 195
8.3.2 ENDOMETRIAL STROMAL SARCOMA 195
8.3.2.1 INSTRUMENT-BASED 195
8.3.2.1.1 ULTRASOUND SCANNING 195
8.3.2.1.2 IMAGING DEVICES 196
8.3.2.1.3 TESTS 196
8.3.2.1.4 OTHERS 196
8.3.2.2 PROCEDURE-BASED 196
8.3.2.2.1 ENDOMETRIAL BIOPSY 196
8.3.2.2.2 HYSTEROSCOPY 196
8.3.2.2.3 DILATION & CURETTAGE 197
8.3.2.2.4 CYSTOSCOPY 197
8.3.2.2.5 PROCTOSCOPY 197
8.3.2.2.6 OTHERS 197
8.3.3 UNDIFFERENTIATED SARCOMA 197
8.3.3.1 INSTRUMENT-BASED 198
8.3.3.1.1 ULTRASOUND SCANNING 198
8.3.3.1.2 IMAGING DEVICES 198
8.3.3.1.3 TESTS 198
8.3.3.1.4 OTHERS 198
8.3.3.2 PROCEDURE-BASED 199
8.3.3.2.1 ENDOMETRIAL BIOPSY 199
8.3.3.2.2 HYSTEROSCOPY 199
8.3.3.2.3 DILATION & CURETTAGE 199
8.3.3.2.4 CYSTOSCOPY 199
8.3.3.2.5 PROCTOSCOPY 200
8.3.3.2.6 OTHERS 200
9 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 201
9.1 OVERVIEW 202
9.2 >60 YEARS 205
9.3 51-60 YEARS 206
9.4 41-50 YEARS 207
9.5 31-40 YEARS 208
9.6 <30 YEARS 209
10 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 210
10.1 OVERVIEW 211
10.2 HOSPITALS 214
10.3 DIAGNOSTIC CENTERS 215
10.4 CANCER RESEARCH CENTERS 216
10.5 AMBULATORY SURGICAL CENTERS 217
10.6 SPECIALIZED CLINICS 218
10.7 OTHERS 219
11 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 220
11.1 OVERVIEW 221
11.2 DIRECT TENDER 224
11.3 THIRD PARTY DISTRIBUTORS 225
11.4 OTHERS 226
12 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 227
12.1 NORTH AMERICA 228
12.1.1 U.S. 244
12.1.2 CANADA 255
12.1.3 MEXICO 266
13 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 279
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 279
14 SWOT ANALYSIS 280
15 COMPANY PROFILE 281
15.1 KONINKLIJKE PHILIPS N.V. 281
15.1.1 COMPANY SNAPSHOT 281
15.1.2 REVENUE ANALYSIS 281
15.1.3 COMPANY SHARE ANALYSIS 282
15.1.4 PRODUCT PORTFOLIO 282
15.1.5 RECENT DEVELOPMENTS 282
15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED. 284
15.2.1 COMPANY SNAPSHOT 284
15.2.2 COMPANY SHARE ANALYSIS 284
15.2.3 PRODUCT PORTFOLIO 285
15.2.4 RECENT DEVELOPMENTS 285
15.3 GENERAL ELECTRIC COMPANY 286
15.3.1 COMPANY SNAPSHOT 286
15.3.2 REVENUE ANALYSIS 286
15.3.3 COMPANY SHARE ANALYSIS 287
15.3.4 PRODUCT PORTFOLIO 287
15.3.5 RECENT DEVELOPMENTS 287
15.4 SIEMENS HEALTHCARE GMBH 289
15.4.1 COMPANY SNAPSHOT 289
15.4.2 REVENUE ANALYSIS 289
15.4.3 COMPANY SHARE ANALYSIS 290
15.4.4 PRODUCT PORTFOLIO 290
15.4.5 RECENT DEVELOPMENTS 290
15.5 FUJIFILM CORPORATION 291
15.5.1 COMPANY SNAPSHOT 291
15.5.2 REVENUE ANALYSIS 291
15.5.3 COMPANY SHARE ANALYSIS 292
15.5.4 PRODUCT PORTFOLIO 292
15.5.5 RECENT DEVELOPMENTS 292
15.6 AED.MD 294
15.6.1 COMPANY SNAPSHOT 294
15.6.2 PRODUCT PORTFOLIO 294
15.6.3 RECENT DEVELOPMENTS 294
15.7 ARQUER DIAGNOSTICS LTD 295
15.7.1 COMPANY SNAPSHOT 295
15.7.2 PRODUCT PORTFOLIO 295
15.7.3 RECENT DEVELOPMENTS 295
15.8 B. BRAUN SE 296
15.8.1 COMPANY SNAPSHOT 296
15.8.2 PRODUCT PORTFOLIO 296
15.8.3 RECENT DEVELOPMENTS 296
15.9 ESAOTE SPA 297
15.9.1 COMPANY SNAPSHOT 297
15.9.2 PRODUCT PORTFOLIO 297
15.9.3 RECENT DEVELOPMENTS 297
15.10 F. HOFFMANN-LA ROCHE LTD 299
15.10.1 COMPANY SNAPSHOT 299
15.10.2 REVENUE ANALYSIS 299
15.10.3 PRODUCT PORTFOLIO 300
15.10.4 RECENT DEVELOPMENTS 300

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.